Author

F. Pereira-Dutra

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

C. Q. Sacramento· 2 shared J. R. Temerozo· 2 shared N. Fintelman-Rodrigues· 2 shared P. T. Bozza· 2 shared T. M. L. Souza· 2 shared A. C. Ferreira· 1 shared A. d. P. D. Da Silva· 1 shared A. Owen· 1 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

C. Q. Sacramento

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication by targeting its major protease in a non-competitive way

O. A. Chaves, C. Q. Sacramento, N. Fintelman-Rodrigues, J. R. Temerozo, F. Pereira-Dutra, D. M. Mizurini, R. Q. Monteiro, L. Vazquez, P. T. Bozza, H. C. Castro-Faria-Neto, T. M. L. Souza

This study shows apixaban inhibits SARS-CoV-2 replication by targeting its Mpro protease non-competitively, with higher potency than boceprevir.

bioRxiv · Sep 23, 2021 · PreprintMicrobiology

Unlike Chloroquine, mefloquine inhibits SARS-CoV-2 infection in physiologically relevant cells and does not induce viral variants.

C. Q. Sacramento, N. Fintelman-Rodrigues, S. S. G. Dias, J. R. Temerozo, A. d. P. D. Da Silva, C. S. da Silva, A. C. Ferreira, M. Mattos, V. C. Soares, F. Pereira-Dutra, M. D. Miranda, D. F. Barreto-Vieira, M. A. N. da Silva, S. de Siqueira Santos, M. Torres, , T. M. L. Souza

This paper shows mefloquine inhibits SARS-CoV-2 infection in relevant cells more effectively than chloroquine without promoting viral mutations.

bioRxiv · Jul 21, 2021Microbiology